EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Liquid Biopsies in Lung Cancer

Marcel Kemper iD, Carolin Krekeler, Kerstin Menck iD, Georg Lenz, Georg Evers, Arik Bernard Schulze iD, Annalen Bleckmann

Cancers · 23.02.2023 · 15 (5) · 1430

DOI: 10.3390/cancers15051430 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.02.2023. Verfasst von Marcel Kemper und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Muenster, 48149 Muenster, Germany. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 257 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Ministry of Education and Research (BMBF), the Else Kröner-Fresenius-Stiftung, University of Münster.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As lung cancer has the highest cancer-specific mortality rates worldwide, there is an urgent need for new therapeutic and diagnostic approaches to detect early-stage tumors and to monitor their response to the therapy. In addition to the well-established tissue biopsy analysis, liquid-biopsy-based assays may evolve as an important diagnostic tool. The analysis of circulating tumor DNA (ctDNA) is the most established method, followed by other methods such as the analysis of circulating tumor cells (CTCs), microRNAs (miRNAs), and extracellular vesicles (EVs). Both PCR- and NGS-based assays are used for the mutational assessment of lung cancer, including the most frequent driver mutations. However, ctDNA analysis might also play a role in monitoring the efficacy of immunotherapy and its recent accomplishments in the landscape of state-of-the-art lung cancer therapy. Despite the promising aspects of liquid-biopsy-based assays, there are some limitations regarding their sensitivity (risk of false-negative results) and specificity (interpretation of false-positive results). Hence, further studies are needed to evaluate the usefulness of liquid biopsies for lung cancer. Liquid-biopsy-based assays might be integrated into the diagnostic guidelines for lung cancer as a tool to complement conventional tissue sampling.

Schlagwörter

Stichwörter der Autor:innen

CTCEVctDNAliquid biopsylung cancermiRNA

Autor:innen und Institutionen

  • Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Muenster, 48149 Muenster, Germany.
  • West German Cancer Center, University Hospital Muenster, 48149 Muenster, Germany.

ORCID-Profile: Marcel Kemper, Kerstin Menck, Arik Bernard Schulze

Förderung

  • German Ministry of Education and Research (BMBF)
  • the Else Kröner-Fresenius-Stiftung
  • University of Münster
  • the Excellence Cluster
  • Volkswagen Foundation
  • Novartis Pharma GmbH
  • Medical Faculty
  • German Ministry of Education and Research (BMBF) e:Med project MyPathSem

Zitieren

APA

Kemper, M., Krekeler, C., Menck, K., Lenz, G., Evers, G., Schulze, A. B., & Bleckmann, A. (2023). Liquid Biopsies in Lung Cancer. Cancers, 15(5), 1430. https://doi.org/10.3390/cancers15051430

Vancouver

Kemper M, Krekeler C, Menck K, Lenz G, Evers G, Schulze AB, et al. Liquid Biopsies in Lung Cancer. Cancers. 2023;15(5):1430. doi:10.3390/cancers15051430

BibTeX
@article{Kemper2023,
  author = {Kemper, Marcel and Krekeler, Carolin and Menck, Kerstin and Lenz, Georg and Evers, Georg and Schulze, Arik Bernard and Bleckmann, Annalen},
  title = {Liquid Biopsies in Lung Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {5},
  pages = {1430},
  doi = {10.3390/cancers15051430}
}
Kostenlos starten →